IL-17A/IL-17RA interaction inhibitors disclosed in Janssen patent
Oct. 21, 2024
Work at Janssen Pharmaceutica NV has led to the identification of lactam-containing imidazopyridazine interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction inhibitors.